# Compare CJC-1295, CJC-1295/Ipamorelin, Ipamorelin, and Tesamorelin — Long Island Peptides

> A side-by-side comparison of four Growth Hormone Axis research peptides — CJC-1295, CJC-1295/Ipamorelin, Ipamorelin, and Tesamorelin — across mechanism, evidence maturity, and regulatory status.

How a GHRH analog, a ghrelin-receptor agonist, their combination, and an FDA-approved analog differ in mechanism, evidence, and what has actually been proven.

## The short version

This page lines up all four Growth Hormone Axis peptides on this guide — [CJC-1295](/cjc-1295), [CJC-1295/Ipamorelin](/cjc1295-ipamorelin), [Ipamorelin](/ipamorelin), and [Tesamorelin](/tesamorelin) — on the dimensions that matter most: which receptor each one acts on, how mature the evidence behind it is, and where it stands with regulators. The short answer: two of the four (CJC-1295 and tesamorelin) work through the same GHRH receptor but with very different chemistry and very different regulatory histories; ipamorelin works through a completely separate receptor; and the combination of the two mechanisms has never itself been tested in a controlled trial. Only tesamorelin is FDA-approved, and only for one specific condition. Nothing on this page is medical advice, and no dose is recommended for any individual.

## The comparison matrix

| Dimension | CJC-1295 | CJC-1295 / Ipamorelin | Ipamorelin | Tesamorelin |
| --- | --- | --- | --- | --- |
| Receptor target | GHRH receptor (GHRHR) | GHRH receptor + ghrelin receptor (GHS-R1a) | Ghrelin receptor (GHS-R1a) only | GHRH receptor (GHRHR) |
| Duration of action | Multi-day (DAC form, albumin-bound); short-acting no-DAC variant also exists | Multi-day (CJC-1295 half) layered with a short pulse (ipamorelin half) | Short — roughly 2-hour half-life, single GH pulse | Short — daily dosing |
| Deepest human evidence | Small pharmacology studies, healthy adults, mid-2000s [4][5] | None for the fixed combination itself; inferred from single-agent data [10] | One Phase 2 surgical trial (missed primary endpoint) [13] | Multiple RCTs plus a 2026 five-trial meta-analysis [8][17][19] |
| Regulatory status | Not approved; research chemical | Not approved; research chemical (both components) | Not approved; research chemical | FDA-approved (2010), HIV-associated lipodystrophy only |
| Distinctive research finding | Multi-day GH/IGF-1 elevation from a single dose [4] | Receptor co-activation roughly doubles the cAMP signal in vitro [10] | Selective for GH release without raising cortisol or prolactin [15] | Preferential reduction of visceral fat, sustained to 52 weeks [19] |
| Key caution | Sustained IGF-1 elevation; fluid retention; unapproved [1][4] | Untested fixed blend; mismatched component timescales [4][7][9] | Thin human data; class-level cardiotoxicity signal in a related compound [12][13] | Narrow approved indication; benefit reverses on stopping [19] |

## Mechanism: two receptors, one axis

CJC-1295 and tesamorelin both work by copying GHRH, the natural signal that tells the pituitary gland's somatotroph cells to release growth hormone — they bind the same receptor (GHRHR) and trigger the same intracellular cascade. Ipamorelin works through an entirely separate route: the ghrelin receptor (GHS-R1a), normally activated by the stomach hormone ghrelin, which uses a different second-messenger system (calcium rather than cyclic AMP) [15]. Because these two receptor systems are mechanistically independent, laboratory work co-activating both in engineered cells found the combined signal was roughly double the GHRH-receptor signal alone — the basic rationale behind the CJC-1295/Ipamorelin combination [10]. The chemistry that sets duration also varies widely: CJC-1295's DAC variant is bonded to serum albumin for a multi-day effect [7], tesamorelin is chemically stabilized but still dosed daily, and ipamorelin's own half-life is around two hours [14].

## Evidence maturity

This is where the four genuinely separate. Tesamorelin has by far the deepest evidence base: multiple randomized controlled trials feeding into a 2026 meta-analysis of five RCTs, plus a dedicated long-term 52-week program and a mechanistic study in healthy volunteers [8][17][18][19]. CJC-1295's human data are older and narrower — a small number of pharmacology studies in healthy adults from 2006, with nothing larger or more recent since [3][4][5][6]. Ipamorelin's evidence is thinner still: one Phase 2 human trial, which missed its primary endpoint, plus a small pharmacokinetic study and preclinical work in rats and ferrets [11][13][14][15]. The CJC-1295/Ipamorelin combination has the thinnest evidence of all — no trial has ever tested the fixed pairing, so everything about it is inferred from the other three compounds' separate literatures plus older receptor-interaction data [10].

## Regulatory status

Tesamorelin is the only FDA-approved compound in this guide, cleared in 2010 for one specific indication — reducing excess abdominal fat in HIV-associated lipodystrophy — and every other use is off-label [16]. CJC-1295, ipamorelin, and the CJC-1295/Ipamorelin combination are all unapproved research chemicals with no FDA-sanctioned human use; CJC-1295 and ipamorelin were both reviewed (and, for ipamorelin, removed from a compounding bulk-substances category) at recent FDA Pharmacy Compounding Advisory Committee meetings, citing immunogenicity and purity concerns. All four compounds are prohibited in sport at all times under the WADA peptide-hormone category (Section S2).

## Key caution

Each compound carries a defining caveat worth holding onto. For CJC-1295, it's that raising GH and IGF-1 for days at a time — its whole design goal — comes with mechanism-based, not proven, questions about IGF-1 and cancer risk, plus consistently reported fluid retention [4]. For CJC-1295/Ipamorelin, it's that the fixed combination has never been tested, and its two halves work on very different timescales, so the actual GH exposure produced by any specific protocol is inferred rather than measured [4][7][9]. For ipamorelin, it's the thinness of the human evidence — one trial that missed its endpoint — paired with a class-level cardiotoxicity signal from a related (not identical) ghrelin-receptor agonist [12][13]. For tesamorelin, it's that its real trial strength is narrowly scoped to one population and one condition, and its benefit reverses within weeks of stopping [19]. Reading the four together, the pattern is consistent: the compounds with the most mechanistic ambition (multi-day duration, combined receptor targeting) tend to have the thinnest direct evidence, while the one compound with deep trial support has the narrowest approved use.

---

Long Island Peptides is an independent field guide to GH-axis research — every claim here arrives with its citation, and every citation arrives with its caveat.